Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 2.6/5
Laurus Labs (LAURUS IN)
Watchlist
Contact IR
62
Analysis
Health Care
•
India
Laurus Labs Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India and internationally. It offers APIs for anti-retroviral and hepatitis C; and APIs in oncology and other therapeutic areas. .
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
SAI Life Sciences
•
10 Dec 2024 09:37
SAI Life Sciences IPO- Growing and Profitable Business; Aggressive Pricing Limits Upside Potential
SAI Life Sciences intends to raise INR9.5B via India IPO. The IPO proceeds will be used for debt repayment. Marquee clientele and diverse portfolio...
Tina Banerjee
Follow
503 Views
Share
bearish
•
NTPC Ltd
•
26 Sep 2024 01:54
NIFTY Indices: Flows (Post Capping) At the Close Tomorrow; Round-Trip US$3.3bn
The next rebalance of the Nifty family of indices takes place at the close on 27 Sep. The round-trip trade is US$3.3bn and there are 13 stocks with...
Brian Freitas
Follow
611 Views
Share
bullish
•
Thematic (Sector/Industry)
•
10 Sep 2024 06:39
The US Biosecure Act: A Boon for Indian CDMO Players?
The Biosecure Act passed by the U.S. House could boost Indian CDMOs as alternative to Chinese biotechs by 2032, leading to potential growth...
Nimish Maheshwari
Follow
662 Views
Share
bullish
•
Thematic (Sector/Industry)
•
04 Sep 2024 03:30
SEBI's F&O Criteria Revision & Its Impact
SEBI introduces stricter F&O eligibility criteria, impacting market liquidity and stability by including 80 stocks and excluding 18 to 23. #SEBI...
Nimish Maheshwari
Follow
572 Views
Share
bullish
•
Hitachi Energy India
•
25 Aug 2024 04:00
NIFTY MIDCAP150 Index Rebalance: 19 Changes a Side; Lots of Overlap with Other Index Flow
There are 19 changes for the index in Sep. Estimated one-way turnover is 9.8% resulting in a one-way trade of INR 8.2bn (US$98m). There are many...
Brian Freitas
Follow
555 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.3
x